Classification of Cholinergic Drugs

This page outlines the classification of cholinergic drugs. They are broadly categorized into cholinergic agonists (cholinomimetic drugs) and cholinergic antagonists. Cholinergic agonists are further divided into direct-acting and indirect-acting drugs.

Direct-acting cholinomimetics activate muscarinic and nicotinic receptors directly. They include choline esters and alkaloids. Indirect-acting cholinomimetics increase acetylcholine levels by inhibiting acetylcholinesterase. These include organophosphates and carbamates.

Definition: Cholinomimetic drugs are substances that mimic the action of acetylcholine in the body.

Example: Bethanechol is a direct-acting cholinomimetic used to treat urinary retention.

Cholinergic Agonists: Direct-Acting Drugs

This page focuses on direct-acting cholinergic agonist drugs. Choline esters, a subclass of direct-acting cholinomimetics, include acetylcholine (the prototype), bethanechol (for urinary retention), carbachol (for glaucoma), and methacholine (for asthma diagnosis).

Alkaloids, another subclass of direct-acting cholinomimetics, include pilocarpine, which is the drug of choice for emergency lowering of intraocular pressure in acute angle-closure glaucoma.

The page also mentions edrophonium, an indirect-acting cholinergic drug used in the diagnosis of myasthenia gravis through the Tensilon test.

Highlight: Pilocarpine is crucial in the emergency treatment of acute angle-closure glaucoma.

Vocabulary: Myasthenia gravis - An autoimmune disorder characterized by muscle weakness due to damaged acetylcholine receptors.

Indirect-Acting Cholinergic Drugs and Cholinergic Antagonists

This page covers indirect-acting cholinergic drugs and introduces cholinergic antagonists. Carbamates, a class of indirect-acting cholinergics with intermediate duration, include physostigmine (used as an antidote for anticholinergic poisoning) and neostigmine (the drug of choice for myasthenia gravis treatment).

Organophosphates, another class of indirect-acting cholinergics with long duration, include drugs used for glaucoma treatment and insecticides. The antidote for organophosphate poisoning is pralidoxime (PAM) along with atropine.

The page also introduces cholinergic antagonists, which block cholinergic receptors. These are classified based on the type of receptor they block: muscarinic or nicotinic.

Example: Physostigmine is used as an antidote for anticholinergic poisoning caused by atropine, phenothiazines, or tricyclic antidepressants.

Highlight: The combination of pralidoxime and atropine is crucial in treating organophosphate poisoning.

Muscarinic Blockers and Their Effects

This page focuses on muscarinic blockers, a type of cholinergic antagonist. Atropine is the prototype muscarinic blocker, with various derivatives used for different purposes. For instance, hyoscine (scopolamine) is used to prevent motion sickness, often administered as a transdermal patch.

The page describes the classic anticholinergic effects using the mnemonic "dry as a bone, blind as a bat, hot as a hare, red as a beet." These effects include dry mouth, blurred vision, hyperthermia, and flushed skin.

Various muscarinic blockers are listed with their specific uses, such as ipratropium and tiotropium for asthma and COPD, and drugs like oxybutynin and tolterodine for overactive bladder.

Vocabulary: Anticholinergic effects - The physiological effects resulting from the blocking of acetylcholine receptors.

Example: Ipratropium, a quaternary derivative of atropine, is used as a bronchodilator in asthma treatment due to its more peripheral effects on the lungs and reduced CNS effects.

Ganglionic and Neuromuscular Blockers

This final page discusses ganglionic blockers and neuromuscular blockers, both types of cholinergic antagonists. Ganglionic blockers, such as hexamethonium, block neurotransmission at nicotinic receptors in autonomic ganglia.

Neuromuscular blockers are divided into two categories:

1. Non-depolarizing, competitive, reversible blockers (e.g., tubocurarine, atracurium) used as muscle relaxants.
2. Depolarizing, irreversible, non-competitive blockers, with succinylcholine being the only one in clinical use.

The page highlights the risk of malignant hyperthermia associated with succinylcholine use, a life-threatening condition caused by excessive calcium release due to overactivation of ryanodine receptors.

Highlight: Succinylcholine, the only depolarizing muscle relaxant in clinical use, can cause malignant hyperthermia, a potentially fatal complication.

Vocabulary: Malignant hyperthermia - A severe reaction to certain anesthetic drugs, characterized by rapid temperature increase, muscle rigidity, and metabolic acidosis.

Acetylcholine Synthesis and Action

This page illustrates the synthesis, release, and degradation of acetylcholine at synapses. Acetylcholine is synthesized in the presynaptic neuron from choline and acetyl-CoA. It is then packaged into synaptic vesicles and released into the synaptic cleft when an action potential arrives. Acetylcholine binds to receptors on the postsynaptic membrane to transmit the signal. Acetylcholinesterase rapidly breaks down acetylcholine in the synaptic cleft to terminate its action.

Vocabulary: Acetylcholinesterase - The enzyme that breaks down acetylcholine in the synaptic cleft.

Highlight: The recycling of choline back into the presynaptic neuron is an important step in maintaining acetylcholine synthesis.